Elizabeth D. Pulte

Hematology

1015 Chestnut St Ste 1020
Philadelphia, PA 19107

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Real-World Treatment Patterns and Outcomes Among Patients With Newly Diagnosed AML in the United States.

Real-World Treatment Patterns and Outcomes Among Patients With Newly Diagnosed AML in the United States.

Journal: JCO oncology practice

Published: April 30, 2026

US Food and Drug Administration Approval Summary: Imetelstat for Selected Patients With Low- to Intermediate-1 Risk Myelodysplastic Syndromes With Transfusion-Dependent Anemia.

US Food and Drug Administration Approval Summary: Imetelstat for Selected Patients With Low- to Intermediate-1 Risk Myelodysplastic Syndromes With Transfusion-Dependent Anemia.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: October 24, 2025

FDA Approval Summary: Ivosidenib for Treatment of Adult Patients with Relapsed/Refractory Myelodysplastic Syndrome with an IDH1 Mutation.

FDA Approval Summary: Ivosidenib for Treatment of Adult Patients with Relapsed/Refractory Myelodysplastic Syndrome with an IDH1 Mutation.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: March 19, 2025

Perspectives on drug development in chronic myelomonocytic leukemia: changing the paradigm.

Perspectives on drug development in chronic myelomonocytic leukemia: changing the paradigm.

Journal: Blood

Published: June 07, 2024

Complete remission with partial hematological recovery as a palliative endpoint for treatment of acute myeloid leukemia.

Complete remission with partial hematological recovery as a palliative endpoint for treatment of acute myeloid leukemia.

Journal: Blood

Published: December 14, 2023

Treatment of Acute Myeloid Leukemia in the Community Setting.

Treatment of Acute Myeloid Leukemia in the Community Setting.

Journal: The oncologist

Published: July 26, 2023

Eligibility criteria and enrollment of a diverse racial and ethnic population in multiple myeloma clinical trials.

Eligibility criteria and enrollment of a diverse racial and ethnic population in multiple myeloma clinical trials.

Journal: Blood

Published: October 11, 2022

Response Rate, Event-Free Survival, and Overall Survival in Newly Diagnosed Acute Myeloid Leukemia: US Food and Drug Administration Trial-Level and Patient-Level Analyses.

Response Rate, Event-Free Survival, and Overall Survival in Newly Diagnosed Acute Myeloid Leukemia: US Food and Drug Administration Trial-Level and Patient-Level Analyses.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: December 10, 2021

FDA Approval Summary: Revised Indication and Dosing Regimen for Ponatinib Based on the Results of the OPTIC Trial.

FDA Approval Summary: Revised Indication and Dosing Regimen for Ponatinib Based on the Results of the OPTIC Trial.

Journal: The oncologist

Published: August 18, 2021

Analysis of racial and ethnic disparities in multiple myeloma US FDA drug approval trials.

Analysis of racial and ethnic disparities in multiple myeloma US FDA drug approval trials.

Journal: Blood advances

Published: June 08, 2021

FDA Approval Summary: Gilteritinib for Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation.

FDA Approval Summary: Gilteritinib for Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: November 03, 2020

U.S. Food and Drug Administration Benefit-Risk Assessment of Nilotinib Treatment Discontinuation in Patients with Chronic Phase Chronic Myeloid Leukemia in a Sustained Molecular Remission.

U.S. Food and Drug Administration Benefit-Risk Assessment of Nilotinib Treatment Discontinuation in Patients with Chronic Phase Chronic Myeloid Leukemia in a Sustained Molecular Remission.

Journal: The oncologist

Published: November 06, 2018

Showing 1-12 of 19

Last Updated: 09/26/2026